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Abstract
Background: Migration of metastatic tumor cells from the bloodstream into lymph nodes is thought to be
facilitated by expression of the chemokine receptors CCR7, CXCR4 and, for B cell-derived tumors, CXCR5. Expression
of their respective chemokine ligands (CCL19, CCL21, CXCL12 and CXCL13) by endothelial cells inside the lymph
nodes facilitates the trans-endothelial migration (TEM) of these cells through high endothelial venules into the
lymph node parenchyma. It is known that CXCR7, a second CXCL12 receptor, regulates TEM of CXCR4+CXCR7+
tumor cells towards a CXCL12 source. In this study, we set out to assess the potential stimulation by CXCL12 of
tumor cell TEM towards other chemokines and whether CXCR7 might be able to regulate such effects.
Methods: The human Burkitt’s lymphoma cell line NC-37, which expresses CXCR4, CXCR5, CXCR7 and CCR7, was
selected as a model system. TEM of these cells through a human HUVEC endothelial cell monolayer was used as
the main model system for these studies. Regulation of their TEM behavior by various concentrations of the
various cognate chemokines for the above-mentioned receptors, placed in either the source or target wells of
modified Boyden chamber migration plates, was assessed by quantifying the number of cells migrated under each
experimental condition.
Results: Exposure of CXCR4
+CXCR7
+ cancer cells to CXCL12 greatly potentiated their TEM towards the chemokines
CCL19 and CXCL13. This CXCL12-potentiated TEM was inhibited by the second CXCR7 chemokine ligand, CXCL11,
as well as CXCR7-specific small molecule antagonists and antibodies. In contrast, the CXCR4 antagonist AMD3100
was less effective at inhibiting CXCL12-potentiated TEM. Thus, CXCR7 antagonists may be effective therapeutic
agents for blocking CXCL12-mediated migration of CXCR4
+CXCR7
+ tumor cells into lymph nodes, regardless of
whether the cancer cells follow a CXCL12 gradient or whether serum CXCL12 stimulates their migration towards
CCR7 and CXCR5 chemokines in the lymph nodes.
Background
Trans-endothelial migration (TEM) is a critical step in the
metastatic dissemination of malignant cells from a primary
tumor to distant vital organs, which is the primary cause
of morbidity and mortality in cancer patients (reviewed in
[1]). During metastasis, cancer cells in the bloodstream
cross the endothelial cell layer of the blood vessel to enter
the parenchyma of the target organ, in a manner similar
to the extravasation of leukocytes. Metastasis of tumor
cells to lymph nodes, whether from blood or directly via
the lymphatics, is likely mediated by the same processes
used by lymphocytes when they enter lymph nodes [2].
Like primary lymphocytes, tumor cells of hematopoietic
and non-hematopoietic origin can express multiple
chemokine receptors. CXCR4 is the most common che-
mokine receptor expressed by cancer cells, and has been
thoroughly implicated in metastasis [3-6]. In model sys-
tems, CXCR4 regulates cancer metastasis to lymph node,
bone, liver, and lung, the four most common metastatic
destinations, which also express high levels of CXCL12,
the only known chemokine ligand for CXCR4 [3-6]. High
levels of CXCL12 are also present in the bloodstream
[7-10].
CCR7, the most studied lymph node homing chemo-
kine receptor, is expressed by certain cancer cells, in par-
ticular hematopoietic malignancies and lymph node
metastases [3], as well as naïve T and B cells, while
CCL19 and CCL21, the chemokine ligands for this recep-
tor, are expressed in the T cell areas of lymph nodes [11].
Similarly, the chemokine receptor CXCR5, which guides * Correspondence: jjaen@chemocentryx.com
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follicles [11], has been detected on leukemia and lym-
phoma cells and on naïve B cells [12-15].
A poorly understood but important area of chemokine
biology is the synergistic and/or inhibitory effects pro-
duced by simultaneous activation or inhibition of multi-
ple chemokine receptors. For example, CXCL12 has been
shown to potentiate the chemotaxis of CXCR4+ cells
towards CCL19, CCL21 or CXCL13. In one report,
CXCL12 treatment increased T cell responsiveness to
CCL19 and CCL21 in vitro and increased CCR7-depen-
dent recruitment of T cells into lymph nodes in vivo [16].
Moreover, Okada et al. showed that CXCL12-treated T
cells homed more efficiently to lymph nodes and Peyer’s
patches than non-treated cells [17].
CXCR7 was recently identified as a second, high-affinity
receptor for CXCL12 [18]. This receptor is highly
expressed by a variety of cancers, including breast [19],
brain [20,21], liver [22], pancreas [23], lung [24], prostate
[25], melanoma [26,27] and rhabdosarcomas [28]. Like
CXCR4, CXCR7 has also been implicated in tumor metas-
tasis [24,28,29]. We recently showed that, although it does
not directly mediate cell migration, CXCR7 can regulate
TEM of CXCR4
+CXCR7
+ tumor cells towards CXCL12,
an effect that can be blocked by CXCR7-specific antago-
nists and the second CXCR7 chemokine ligand, CXCL11
[30]. We now describe that CXCL12 may enhance cell
homing to lymph nodes by potentiating TEM towards
CCL19, CCL21 and CXCL13, and show that CXCR7 can
regulate this CXCL12-mediated potentiation of TEM. In
the current study, we have studied the CXCL12-mediated
TEM of Burkitt’s lymphoma cells toward CCL19 and
CXCL13. We then evaluated the involvement of CXCR7
by assessing the ability of CXCL11 and CXCR7-specific
antagonists to interfere with such TEM. These studies
illustrate a potential mechanism by which tumor cells
metastasize to lymph nodes and other tissues, providing
the rationale for antagonizing CXCR7 in vivo in order to
block tumor metastasis.
Methods
Cells and reagents
The human Burkitt’s lymphoma cell line NC-37 was
obtained from the American Type Culture Collection
(Manassas, VA). Human umbilical vein endothelial cells
(HUVEC) were obtained from Lonza, Inc. (San Jose, CA),
cultured according to the manufacturer’s specifications,
and used at passage 3. Chemokines CCL2, CCL19,
CXCL9, CXCL11, CXCL12, and CXCL13 were purchased
f r o mR & DS y s t e m s( M i n n e a p o l i s ,M N ) .A n t i - C C R 7
(clone 150503), -CXCR3 (49801), -CXCR4 (12G5),
-CXCR5 (clone RF8B2), and mouse IgG2a isotype control
mAbs were also purchased from R&D Systems. Anti-
CXCR7 (clone 8F11) and mouse IgG2b isotype control
mAbs were purchased from BioLegend (San Diego, CA).
PE-conjugated goat anti-mouse IgG was purchased from
Jackson ImmunoResearch Labs, Inc. (West Grove, PA).
Anti-CXCR7 (clone 11G8) mAb, mouse IgG1 isotype
control mAb, CCX771 and CCX704 [30] were generated
at ChemoCentryx, Inc. AMD3100 was purchased from
Sigma Aldrich (St. Louis, MO). Flow cytometry was per-
formed on a FACScan (BD Biosciences, San Jose, CA).
Bare filter chemotaxis assay
Chemokine was diluted in chemotaxis buffer (HBSS con-
taining 0.1% BSA), 29 μl/well was transferred to a 96-well
microchamber plate, and the plate was covered with a
5 μm 96-well filter (NeuroProbe, Gaithersburg, MD).
NC-37 cells were resuspended at 1 × 10
7cells/ml in che-
motaxis buffer, mixed with chemokine, antibody or com-
pound, and 20 μl/well was added on top of the filter. The
plate was incubated for 2 h at 37°C in a humidified incu-
bator, the filter was removed, and 5 μl/well of the DNA-
intercalating reagent CyQuant (Invitrogen, Carlsbad, CA)
was added to the wells. Fluorescence was measured using
the SpectraFluor Plus plate reader (TECAN, San Jose, CA).
Trans-endothelial migration assay
The TEM assay was performed using 24-well plates with
microporous (5 μm) transwell membrane inserts (Corning
Costar Corp., Lowell, MA). HUVEC (passage 3) were sus-
pended at 1 × 10
6/ml in HUVEC media (Lonza), 100 μl/
well was placed in the top wells and 600 μl/well of HUVEC
media was placed in the bottom wells. The plate was incu-
bated overnight at 37°C, after which the HUVEC mono-
layers were washed with PBS lacking Ca
2+ and Mg
2+.
NC-37 cells were suspended at 5 × 10
6cells/ml in assay
medium (IMDM (Invitrogen, Carlsbad, CA) with 0.1%
BSA), incubated with test reagents (AMD3100, CCX704,
CCX771, CXCL9, CXCL11, 11G8, mIgG1, 8F11, mIgG2b,
12G5, or mIgG2a) at room temperature for 10 min, and
then added (100 μl/well) to the upper wells containing the
HUVEC monolayers. In potentiated TEM experiments,
CXCL12 was also added to the NC-37 cells. Assay medium
containing CCL2, CCL19, CXCL12, and/or CXCL13 was
then added (600 μl/well) to the bottom wells. The plates
were incubated overnight at 37°C, the top wells were
removed, and the cells in the bottom wells were counted.
RNAi
HUVEC (passage 1-2) were transfected with double-
stranded RNAi oligonucleotides using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
recommendations. Stealth RNAi duplex targeting CXCR7
(RNA sequence (GGCUAUGACACGCACUGCUACA
UCU) and a scramble RNAi duplex control (GC content
48%) were purchased from Invitrogen. HUVEC were col-
lected for the TEM assays three days after transfection.
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Chemokine receptor expression on NC-37 human B
lymphoma cells includes CCR7 and CXCR5
To determine whether NC-37 cells are suitable to model
CXCL12-mediated potentiation of CCL19 or CXCL13-
driven TEM in lymph nodes, we evaluated chemokine
receptor expression by these cells (Figure 1). As shown
in our previous report, NC-37 cells expressed CXCR4
and CXCR7 but not CXCR3 by flow cytometry (Figure
1A and [30]). NC-37 cells also expressed chemokine
receptors CCR7 and CXCR5 but not CCR2 (Figure 1A).
Furthermore, NC-37 cells migrated in a dose-dependent
fashion to CCL19, CXCL13 and CXCL12 in bare filter
transwell chemotaxis assays (Figure 1B). Peak migration
was induced by 4 nM CCL19, 60 nM CXCL13, and
10 nM CXCL12, respectively.
CXCL12 potentiates NC-37 cell TEM to CXCL13
In the TEM assay, NC-37 cells were tested for migration
through a layer of human umbilical vein endothelial cells
(HUVEC) into the bottom well of a 24-well chemotaxis
plate, which contained CXCL13. Despite expressing func-
tional CXCR5, and unlike their behavior in bare filter
assays, NC-37 cells did not migrate across the HUVEC
monolayer to any of the CXCL13 concentrations tested
(from 3 nM to 3 μM, Figure 2). When CXCL12 was pre-
sent in both top and bottom wells, however, the NC-37
cells migrated through the HUVEC monolayer in a con-
centration-dependent manner towards CXCL13. Peak
migration was induced by 300 nM CXCL13 in the lower
well, and the optimal concentration of CXCL12 to stimu-
late this effect was 10 nM. CXCL12 did not induce NC-
37 cell TEM to the CCR2 ligand CCL2 (data not shown),
indicating that CXCL12 potentiation of chemokine-
driven TEM requires the presence of the specific chemo-
kine receptor. Interestingly, the presence of CXCL12 in
both wells also induced some NC-37 cell migration in
the absence of other chemokines; this migration could
result from increased non-directional motility (i.e. che-
mokinesis) of the NC-37 cells and/or increased perme-
ability of the HUVEC monolayer.
A CXCR7-specific compound blocks CXCL12-potentiated
NC-37 cell TEM to CXCL13
We previously reported that the CXCR7-specific antago-
nist CCX771 was 20-fold more potent than the CXCR4-
specific antagonist AMD3100 in blocking NC-37 cell
TEM to CXCL12 [30]. Here we evaluated the effects of
Figure 1 NC-37 cells express functional CXCR5 and CCR7.A :
Flow cytometry analysis of chemokine receptor expression by NC-37
cells. Open histograms show receptor-specific staining; filled
histograms show isotype controls. Relevant controls are color-
matched. B: Assessment of bare filter NC-37 cell migration to a
range of concentrations of CCL19, CXCL12, or CXCL13. The mean ±
SEM of six wells per concentration is shown. Representative of 3
independent experiments.
Figure 2 CXCL12 potentiates NC-37 cell TEM to CXCL13.N C - 3 7
cell TEM to a range of concentrations of CXCL13 in the bottom
well was assessed in the absence (filled black squares) or presence
(open circles) of 10 nM CXCL12 in the top and bottom wells. NC-37
cell TEM in the absence of CXCL13 is indicated by a black square
(absence of CXCL12) and an open circle (CXCL12 in both wells) on
the left. The mean ± range of duplicate wells per condition is
shown. Representative of 3 independent experiments.
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tiated NC-37 cell TEM to CXCL13 (Figure 3). CCX771
was a potent inhibitor of CXCL12-potentiated NC-37
cell TEM to CXCL13, exhibiting an IC50 value of
28 nM. CCX771 also inhibited the non-directional
migration of NC-37 induced by CXCL12 alone, resulting
in near-background levels of migration (data not
shown). In comparison, AMD3100 had only a modest
effect on CXCL12-potentiated TEM to CXCL13, inhibit-
ing < 30% of cell migration. The control compound
CCX704, a homolog of CCX771 with no affinity for
CXCR7, had no effect on CXCL13-potentiated TEM.
CXCR7-specific mAbs and CXCL11 block CXCL12-
potentiated NC-37 cell TEM to CXCL13 or CCL19
We next tested other agents that block CXCL12 binding
to CXCR7 for their effects on CXCL12-potentiated TEM
(Figure 4). The other CXCR7 chemokine ligand,
CXCL11, significantly inhibited CXCL12-potentiated
NC-37 cell TEM to CXCL13, while the CXCR3-specific
chemokine, CXCL9, had no effect (Figure 4A). Anti-
CXCR7 mAbs (clones 11G8 and 8F11) also significantly
blocked potentiated migration in this assay, compared
with their respective isotype controls. CCX771 was the
most effective inhibitor, reducing TEM to background
levels, whereas the control compound CCX704 and
AMD3100 had no effect. Despite the lack of efficacy of
AMD3100, the anti-CXCR4 mAb 12G5 modestly but sig-
nificantly blocked CXCL12-potentiated NC-37 cell TEM
to CXCL13, suggesting that CXCR4 plays a role in the
TEM.
To determine whether these agents could block
CXCL12-potentiated NC-37 cell TEM to other
chemokines, we performed t h es a m ea s s a yw i t ht h e
CCR7 ligand CCL19. Although NC-37 cells migrated to
CCL19 in the bare-filter migration assay (Figure 1), the
cells did not migrate to CCL19 in the TEM assay
(Figure 4B). However, NC-37 cells did migrate to
CCL19 in the TEM assay (optimal concentration 1 μM)
when CXCL12 (10 nM) was present in both wells. As
seen in the TEM assay with CXCL13, CXCL12-poten-
tiated TEM of NC-37 cells to CCL19 was inhibited by
CXCL11, CCX771, and the CXCR7 and CXCR4-specific
mAbs. CXCL9, AMD3100 and CCX704 did not block
migration, supporting the fact that CXCL12 potentiation
of CCL19-driven TEM occurred through CXCR7.
To confirm that CCX771, CXCL11 and the mAbs did
not interfere with TEM by interacting directly with
CXCR5, CXCL13, CCR7, or CCL19, we tested these
agents in the bare filter chemotaxis assay. CCX771,
CXCL11 and the mAbs had no effect on bare filter
migration of NC-37 cells to CXCL13 (Figure 4C) or
CCL19 (Figure 4D), ruling out the possibility of direct
inhibitory effects of these agents on CXCR5 or CCR7 or
their ligands.
CXCR7 expression by HUVEC is dispensable for CCX771
blockade of NC-37 cell TEM
We previously reported that, although the HUVEC used
in the TEM assay express low levels of CXCR7, CCX771
does not inhibit TEM of CXCR4
+CXCR7
- cells to
CXCL12 [30]. This result, however, does not rule out the
possibility that HUVEC-expressed CXCR7 plays a role in
CXCL12-driven (CXCL12 in the bottom well) or
CXCL12-potentiated (CXCL12 in both wells) TEM of
CXCR4
+CXCR7
+ cells. To address this possibility, we
used RNAi methods to reduce CXCR7 protein expression
in HUVEC and then evaluated the cells in the TEM
assay. HUVEC transfected with CXCR7-targeted RNAi
failed to stain with the anti-CXCR7 mAb 11G8 by flow
cytometry, whereas HUVEC transfected with scrambled
duplex RNAi retained 11G8 staining (Figure 5A). CXCR7
knockdown did not affect the ability of CCX771 to block
CXCL12-driven TEM (Figure 5B) or CXCL12-poten-
tiated TEM (Figure 5C). Therefore, the regulation of
CXCL12-driven TEM and CXCL12-potentiated TEM by
CXCR7 appears to occur in the migrating cells, not the
endothelial cells. This result suggests that, in order to
block TEM in vivo, pharmacologic antagonists of CXCR7
need only engage CXCR7 on the tumor cell, not CXCR7
on the endothelium.
In this report we demonstrate that CXCL12 can work in
concert with CCL19 or CXCL13 to promote efficient
TEM of CXCR7
+ Burkitt’s lymphoma NC-37 cells. While
C C L 1 9o rC X C L 1 3a l o n ed i dn o ti n d u c eT E Mo ft h e s e
cells, which also express CCR7, CXCR4, and CXCR5, the
presence of CXCL12 on the apical side or both sides of
Figure 3 CCX771 blocks CXCL12-potentiated NC-37 cell TEM to
CXCL13. NC-37 cell TEM to 300 nM CXCL13 in the presence of 10
nM CXCL12 in both wells was performed in the presence of a range
of concentrations of CCX771 (green squares), CCX704 (red circles) or
AMD3100 (blue diamonds). NC-37 cell TEM in the absence of
chemokines (black square), presence of CXCL12 only (black circle)
and presence of CXCL13 and CXCL12 (but absence of compounds,
black diamond) are indicated on the left. The mean ± range of
duplicate wells per treatment is shown. Representative of 3
independent experiments.
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towards CCL19 or CXCL13. These observations may
relate to metastasis in vivo, since CXCL12 is implicated in
metastasis but is present both in the bloodstream and in
the parenchyma of many organs (reviewed in [3-6]).
Importantly, the sensitization of NC-37 cells by CXCL12
w a sb l o c k e db yaC X C R 7 - s p e c i f i ca n t a g o n i s t .S i n c et h e
antagonist also blocks TEM of the NC-37 cells towards
CXCL12 alone [30], we conclude that CXCR7 can regulate
both CXCL12-directed TEM and CXCL12-potentiated
TEM of CXCR4
+CXCR7
+ lymphoma cells.
In addition to potentiating TEM towards CCL19 and
CXCL13, CXCL12 alone induced TEM. That is, a subset
of NC-37 cells migrated across the endothelial cell layer
when CXCL12 was present at equal concentrations on
both sides of the layer. This non-directed TEM was also
blocked by the CXCR7 antagonist. The CXCR4-specific
antagonist AMD3100 was unable to block either the
non-directed TEM or the CXCL12-potentiated TEM,
supporting the notion that these processes occur through
CXCR7, not CXCR4. In addition, the inhibitory effects of
the CXCR7 antagonist were observed regardless of
whether or not the endothelial monolayer expressed
CXCR7, suggesting that, in vivo, inhibition of TEM might
require pharmacologic antagonism of CXCR7 only on the
tumor cell.
Agents that target CXCR4, a chemokine receptor
expressed by at least 23 different types of cancer [31], can
block tumor cell TEM in mouse models in vivo.T r e a t -
ment of mice with AMD3100 transiently reduced the
seeding of i.v.-injected CXCR4
+ syngeneic 4T1 mammary
tumor cells in the lung [32]. In a xenograft model in
Figure 4 Agents that block CXCL12 binding to CXCR7 inhibit CXCL12-potentiated NC-37 cell TEM to CXCL13 and CCL19. A-B: NC-37 cell
TEM to 300 nM CXCL13 (A) or 1 μM CCL19 (B) in the presence of 10 nM CXCL12 in both wells was performed in the additional presence of the
indicated compounds (red bars), chemokines (blue bars), or mAbs (green bars). Controls (black bars) include TEM in the absence of chemokines,
presence of CXCL13 or CCL19 only, presence of CXCL12 only, and presence of CXCL13 or CCL19 and CXCL12 with no other additions. C-D: NC-
37 cells were analyzed in bare filter chemotaxis assays to 100 nM CXCL13 (C) or 5 nM CCL19 (D) in the presence of the indicated compounds
(red bars), chemokines (blue bars), or mAbs (green bars). Controls (black bars) include chemotaxis in the absence or presence of chemokine with
no other additions. * p-value < 0.05 by Student’s t-test comparing the indicated treatment vs. matched control. For A and B, the mean ± SEM of
triplicate wells per treatment is shown; for C and D, the mean ± SEM of six wells per treatment is shown. Representative of 3 independent
experiments.
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mination of CXCR4
+ human epithelial ovarian carcinoma
cells onto mesothelial cells lining the peritoneal cavity
[33]. In both animal models, however, the effect on
tumor cell dissemination was partial. We previously
showed that AMD3100 was an inefficient inhibitor of
NC-37 cell TEM to CXCL12 [30] and here we show that
AMD3100 is unable to block CXCL12 potentiation of
NC-37 cell TEM to CCL19 or CXCL13. Although our
studies have been performed only with a lymphoma cell
l i n ea n ds h o u l db ee x p a n d e dt oi n c l u d eo t h e rt u m o r
types, it is possible that, for tumor cells that express both
CXCR4 and CXCR7, small molecules that target CXCR7
may therefore prove to be superior agents to inhibit
metastasis in vivo. An additional limitation of our study
is the use of HUVEC cells, which might not recapitulate
the behavior of specialized endothelial cells such as those
found in the high endothelial venules of lymph nodes.
Conclusions
To the extent that the chemokine CXCL12, which is
found in blood and in organs commonly colonized by
Figure 5 CXCR7 expression by HUVEC is dispensable for CCX771 blockade of cell TEM. A: HUVEC were transfected with CXCR7-targeted
RNAi (black open histogram) or scramble-RNAi (red open histogram) oligonucleotides and analyzed by flow cytometry with the CXCR7-specific
mAb 11G8. The filled histogram shows isotype control mAb staining. B: NC-37 cell TEM across CXCR7-targeted RNAi (left graph) or scramble-RNAi
(right graph) HUVEC to 10 nM CXCL12 was performed in the presence of CCX771 or CCX704 (red bars). Controls (black bars) include TEM in the
absence of CXCL12 or the presence of CXCL12 but the absence of compounds. C: NC-37 cell TEM across CXCR7-targeted RNAi (left graph) or
scramble-RNAi (right graph) HUVEC to 300 nM CXCL13 in the presence of 10 nM CXCL12 in both wells was performed in the additional
presence of CCX771 or CCX704 (red bars). Controls (black bars) include TEM in the absence of chemokines, presence of CXCL13 only, presence
of CXCL12 only, and presence of CXCL13 and CXCL12 but the absence of compounds. * p-value < 0.05 by Student’s t-test comparing the
indicated treatment vs. matched control. For B and C, the mean ± SEM of quadruplicate wells per treatment is shown. Representative of 2
independent experiments.
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Page 6 of 8metastatic tumors, participates in promoting the migra-
tion of tumor cells across endothelium into those organs,
our data suggest that the newly discovered CXCR7 recep-
tor for CXCL12 may be a more effective therapeutic
point of intervention than the previously studied CXCR4
receptor, which also recognizes CXCL12.
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